相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer
Olga Kantor et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer
Leonardo Roberto da Silva et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer
Sara A. Hurvitz et al.
CLINICAL CANCER RESEARCH (2020)
Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer
Marcia A. Inda et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Hatem Soliman et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
Aleix Prat et al.
LANCET ONCOLOGY (2020)
Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response
Sarah Boughdad et al.
CANCER IMAGING (2020)
The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis
Yaling Wang et al.
BMC WOMENS HEALTH (2020)
ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.
Cynthia X. Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prediction of Pathologic Complete Response by Ultrasonography and Magnetic Resonance Imaging After Neoadjuvant Chemotherapy in Patients with Breast Cancer
Kai Zhang et al.
CANCER MANAGEMENT AND RESEARCH (2020)
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial
Peter C. Dubsky et al.
EUROPEAN JOURNAL OF CANCER (2020)
Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index
Max A. A. Ragusi et al.
EUROPEAN RADIOLOGY (2020)
Accuracy of breast MRI in patients receiving neoadjuvant endocrine therapy: comprehensive imaging analysis and correlation with clinical and pathological assessments
Joana Reis et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer
Yue Ming et al.
FRONTIERS IN ONCOLOGY (2020)
Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer
Olga Kantor et al.
NPJ BREAST CANCER (2020)
Gauging the efficacy of neoadjuvant endocrine therapy in breast cancer patients with known axillary disease
Jacob B. Hammond et al.
JOURNAL OF SURGICAL ONCOLOGY (2020)
How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?
Giacomo Montagna et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Axillary Response in Patients Undergoing Neoadjuvant Endocrine Treatment for Node-Positive Breast Cancer: Systematic Literature Review and NCDB Analysis
Arielle Stafford et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic
Covadonga Marti et al.
ECANCERMEDICALSCIENCE (2020)
Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines
Lauren I. Madigan et al.
BREAST CANCER RESEARCH (2020)
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study
Hiroji Iwata et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
De-escalated therapy for HR+/HER2+breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study
V Guarneri et al.
ANNALS OF ONCOLOGY (2019)
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Ingrid A. Mayer et al.
CLINICAL CANCER RESEARCH (2019)
Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER plus Breast Cancer
Julie A. Vendrell et al.
FRONTIERS IN PHARMACOLOGY (2019)
A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR plus ) locally advanced/metastatic breast cancer (LABC/MBC).
Joline Si Jing Lim et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Alison Laws et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction
S. Samiei et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
TNeoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Cristina Saura et al.
LANCET ONCOLOGY (2019)
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2019)
Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach
Anna Weiss et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Neoadjuvant Therapy for Breast Cancer as a Model for Translational Research
Cigdem Selli et al.
BREAST CANCER-BASIC AND CLINICAL RESEARCH (2019)
Neoadjuvant palbociclib on ER plus breast cancer (N007): clinical response and EndoPredict's value
Louis W. C. Chow et al.
ENDOCRINE-RELATED CANCER (2018)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling
Lisa Goto-Yamaguchi et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy
Talal Hilal et al.
BREAST JOURNAL (2018)
Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer
Sasagu Kurozumi et al.
PLOS ONE (2018)
Factors Predictive of Response to Hormone Therapy in Breast Cancer
Francesca Rastelli et al.
TUMORI (2018)
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer
P. Cottu et al.
ANNALS OF ONCOLOGY (2018)
Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)
Xu Liang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping
Pat Whitworth et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
18F-Fluoroestradiol PET to Predict the Response to Neoadjuvant Treatment of Luminal Breast Cancer
David Groheux
JOURNAL OF NUCLEAR MEDICINE (2017)
A Randomized Feasibility Study of 18F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor Rich Postmenopausal Breast Cancer
Sun Young Chae et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial
Harry D. Bear et al.
JOURNAL OF SURGICAL ONCOLOGY (2017)
Imaging Neoadjuvant Therapy Response in Breast Cancer
Amy M. Fowler et al.
RADIOLOGY (2017)
Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery
Angel L. Guerrero-Zotano et al.
CANCER DISCOVERY (2017)
Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER plus breast cancer
Matthew J. Ellis
BREAST (2017)
Pre-operative Endocrine Therapy
Laura M. Arthur et al.
CURRENT BREAST CANCER REPORTS (2017)
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer
Cynthia X. Ma et al.
CLINICAL CANCER RESEARCH (2017)
A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072
Rache M. Simmons et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
G. Curigliano et al.
BREAST (2016)
Randomized Phase 2 Neoadjuvant Trial Evaluating Anastrozole and Fulvestrant Efficacy for Postmenopausal, Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: Results of the UNICANCER CARMINA 02 French Trial (UCBG 0609)
Florence Lerebours et al.
CANCER (2016)
Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
P. A. van Dam et al.
EJSO (2016)
Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer
Birgit E. P. J. Vriens et al.
EUROPEAN JOURNAL OF CANCER (2016)
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer A Systematic Review and Meta-analysis
Laura M. Spring et al.
JAMA ONCOLOGY (2016)
Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives
Romualdo Barroso-Sousa et al.
ECANCERMEDICALSCIENCE (2016)
Endocrine therapy as adjuvant or neoadjuvant therapy for breast cancer: selecting the best agents, the timing and duration of treatment
Jun-Jie Li et al.
CHINESE CLINICAL ONCOLOGY (2016)
Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer
Nathalie Quenel-Tueux et al.
BRITISH JOURNAL OF CANCER (2015)
Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer
Arran K. Turnbull et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study
Jean-Francois Boileau et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
One-Year Neoadjuvant Endocrine Therapy in Breast Cancer
Orsolya Rusz et al.
PATHOLOGY & ONCOLOGY RESEARCH (2015)
Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
Pat Whitworth et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer
C. Palmieri et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Optimum duration of neoadjuvant letrozole to permit breast conserving surgery
Robert Carpenter et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review
A. Charehbili et al.
CANCER TREATMENT REVIEWS (2014)
Primary endocrine therapy as a treatment for older women with operable breast cancer - A comparison of randomised controlled trial and cohort study findings
J. L. Morgan et al.
EJSO (2014)
Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients - A phase II trial
Duveken B. Y. Fontein et al.
EUROPEAN JOURNAL OF CANCER (2014)
Evaluating the 21-gene assay Recurrence ScoreA® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer
Takayuki Ueno et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2014)
Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of LetrozoleLapatinib in Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Operable Breast Cancer
Valentina Guarneri et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2013)
Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: A randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy
Takashi Hojo et al.
BREAST (2013)
Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy
Stefan Glueck et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
G. Allevi et al.
BRITISH JOURNAL OF CANCER (2013)
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial
Judy C. Boughey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
Thorsten Kuehn et al.
LANCET ONCOLOGY (2013)
WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
Daniel Hofmann et al.
TRIALS (2013)
A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up
S. J. Johnston et al.
ANNALS OF ONCOLOGY (2012)
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study
E. Alba et al.
ANNALS OF ONCOLOGY (2012)
Hormone Treatment without Surgery for Patients Aged 75 Years or Older with Operable Breast Cancer
C. J. Wink et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[ plus ] operable breast cancer
Antonio Llombart-Cussac et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2012)
MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy
Kazuna Takeda et al.
EUROPEAN JOURNAL OF RADIOLOGY (2012)
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial
Norikazu Masuda et al.
LANCET ONCOLOGY (2012)
Accuracy of Clinical Examination, Digital Mammogram, Ultrasound, and MRI in Determining Postneoadjuvant Pathologic Tumor Response in Operable Breast Cancer Patients
Randal Croshaw et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Invasive lobular carcinoma: response to neoadjuvant letrozole therapy
J. Michael Dixon et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance
Todd W. Miller et al.
CLINICAL CANCER RESEARCH (2011)
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
Martin Filipits et al.
CLINICAL CANCER RESEARCH (2011)
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study
Shigeto Ueda et al.
BREAST CANCER (2011)
Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?
Hiroyuki Takei et al.
BREAST CANCER (2011)
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
G. Osborn et al.
ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND (2011)
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
Marieke E. Straver et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer
Maurizia Mello-Grand et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy.
J. Parker et al.
CANCER RESEARCH (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
Increase in response rate by prolonged treatment with neoadjuvant letrozole
J. Michael Dixon et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer
A. Gil-Rendo et al.
BRITISH JOURNAL OF SURGERY (2009)
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer:: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy
Ute E. Krainick-Strobel et al.
BMC CANCER (2008)
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
Matthew J. Ellis et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer
R. Torrisi et al.
BRITISH JOURNAL OF CANCER (2007)
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer
Vladimir F. Semiglazov et al.
CANCER (2007)
Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review
D. Hind et al.
BRITISH JOURNAL OF CANCER (2007)
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer - The Pre-Operative Arimidex Compared to Tamoxilen (PROAC7) trial
L Cataliotti et al.
CANCER (2006)
Proliferation marker Ki-67 in early breast cancer
A Urruticoechea et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Total mastectomy under local anesthesia: The tumescent technique
GW Carlson
BREAST JOURNAL (2005)
Prediction of docetaxel response in human breast cancer by gene expression profiling
K Iwao-Koizumi et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Cryoablation of early-stage breast cancer: Work-in-progress report of a multi-institutional trial
MS Sabel et al.
ANNALS OF SURGICAL ONCOLOGY (2004)
A gene-expression signature as a predictor of survival in breast cancer.
MJ van de Vijver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
W Eiermann et al.
ANNALS OF ONCOLOGY (2001)
分享论文
